Last reviewed · How we verify
Co-administration of AD-227A and AD-227B
Co-administration of AD-227A and AD-227B is a Small molecule drug developed by Addpharma Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Co-administration of AD-227A and AD-227B |
|---|---|
| Sponsor | Addpharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-administration of AD-227A and AD-227B CI brief — competitive landscape report
- Co-administration of AD-227A and AD-227B updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI
Frequently asked questions about Co-administration of AD-227A and AD-227B
What is Co-administration of AD-227A and AD-227B?
Co-administration of AD-227A and AD-227B is a Small molecule drug developed by Addpharma Inc..
Who makes Co-administration of AD-227A and AD-227B?
Co-administration of AD-227A and AD-227B is developed by Addpharma Inc. (see full Addpharma Inc. pipeline at /company/addpharma-inc).
What development phase is Co-administration of AD-227A and AD-227B in?
Co-administration of AD-227A and AD-227B is in Phase 1.